Effect of trimetazidine on late potentials after acute myocardial infarction

Basit Öğe Kaydı
dc.authoridMuderrisoglu, Haldun/0000-0002-9635-6313
dc.authoridPekdemir, Hasan/0000-0002-4913-5120
dc.authorwosidMuderrisoglu, Haldun/AAG-8233-2020
dc.authorwosidÖZDEMIR, RENK/I-9560-2013
dc.authorwosidPekdemir, Hasan/ABI-6096-2020
dc.contributor.authorÖzdemir, R
dc.contributor.authorTuncer, C
dc.contributor.authorAladag, M
dc.contributor.authorGüven, A
dc.contributor.authorSezgin, AT
dc.contributor.authorPekdemir, H
dc.contributor.authorKorkmaz, ME
dc.date.accessioned2024-08-04T20:12:01Z
dc.date.available2024-08-04T20:12:01Z
dc.date.issued1999
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe purpose of this study was to evaluate the effect of trimetazidine on late potentials in patients with acute myocardial infarction. A total of 60 patients (52 males, mean age 55 +/- 2 years, and 8 females, mean age 54 +/- 1.8 years) with the diagnosis of acute myocardial infarction were included in this study. The study was designed as a randomized, double-blinded, and placebo-controlled trial. Signal-averaged electrocardiography and echocardiography were performed during the first 2 days of acute myocardial infarction and were repeated between days of 8 and 15 (mean 11). Patients were treated with trimetazidine (n = 30) or placebo (n = 30). In the placebo group, the total filtered QRS duration and low-amplitude terminal signal duration increased (from 102.7 +/- 1.8 ms to 113.3 +/- 1.8 ms, and from 32.2 +/- 0.9 ms to 38.3 +/- 1.1 ms; P < 0.001), the root mean square voltage of the terminal 40 ms of the QRS decreased (from 28.6 +/- 2.1 mu V to 21.4 +/- 1.3 mu V; P < 0.001), and the incidence of late potentials increased (from 30% to 46%; P < 0.01) significantly. In the trimetazidine group, these measurements were a decrease from 102.9 +/- 1.9 ms to 100 +/- 2.0 ms (NS), an increase from 31.6 +/- 0.9 ms to 32.5 +/- 0.9 ms (NS), a decrease 9.3 +/- 2.0 mu V to 27.3 +/- 1.8 mu V (P < 0.01), and a decrease from 33% to 30% (NS), respectively. The ejection fraction was 47.1 +/- 1.3% to 50.8 +/- 1.2% in the placebo group (P = 0.05), and 48.1 +/- 1.1% to 53.4 +/- 1.2% (P < 0.01) in the trimetazidine group. It is concluded that trimetazidine reduces late potentials after acute myocardial infarction without changing blood pressure and heart rate.en_US
dc.identifier.doi10.1023/A:1007740311072
dc.identifier.endpage149en_US
dc.identifier.issn0920-3206
dc.identifier.issn1573-7241
dc.identifier.issue2en_US
dc.identifier.pmid10372230en_US
dc.identifier.scopus2-s2.0-0032905384en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://doi.org/10.1023/A:1007740311072
dc.identifier.urihttps://hdl.handle.net/11616/93164
dc.identifier.volume13en_US
dc.identifier.wosWOS:000080730200007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCardiovascular Drugs and Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectacute myocardial infarctionen_US
dc.subjectsignal-averaged electrocardiogramen_US
dc.subjecttrimetazidineen_US
dc.titleEffect of trimetazidine on late potentials after acute myocardial infarctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu